OR5M11

Across TCGA pan-cancer cohorts, OR5M11 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated OR5M11 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher OR5M11 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR5M11 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, DLBC, and BRCA are the cancer types where OR5M11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.195	0.748	.003	15	view →
DLBC	OS	Median	All	0.054	0.842	<.001	12	view →
BRCA	OS	Median	All	0.735	0.963	.019	8	view →
LUSC	OS	Median	II,III,IV	0.431	0.739	.011	6	view →
SCLC	OS	Median	II,III,IV	0.152	0.777	.038	3	view →
ESCA	DFS	Median	All	0.146	0.533	.046	3	view →
UCEC	DFS	Median	All	0.954	0.623	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

OR5M11–ACC (DFS)

Open the ACC breakdown →